Home > Insider Trading > Filing (0000905718-22-000177)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1290149	Sierra Oncology Inc.	SRRA	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1397144	Llp Abingworth	Princes House 38 Jermyn Street London X0 SW1Y 6DN		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, $0.001 Par Value	Acquisiton	2022-01-28	287,471	$13.20	1,164,127	No	4	X	Indirect	See footnote
Common Stock, $0.001 Par Value	Acquisiton	2022-01-31	150,000	$27.00	1,314,127	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	X	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Warrants (right to buy)	Disposition	2022-01-28	287,471	$0.00	287,471	$13.20

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2020-01-22		No	4	X	Indirect

Footnotes

The securities of Sierra Oncology, Inc. (the "Issuer") are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth Bioventures VII GP LP ("Abingworth GP") serves as the general partner of ABV VII. Abingworth General Partner VII LLP, serves as the general partner of Abingworth GP. ABV VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV VII. Abingworth LLP holds the reported securities indirectly through ABV VII. Abingworth LLP disclaims beneficial ownership of such securities, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, ABV VII, Dr. Andrew Sinclair or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Each Series B warrant will expire on the 75th day anniversary of the Issuer's announcement of top-line data from its MOMENTUM Phase 3 clinical trial of momelotinib.